



## Patent Updates

### Suven Life Sciences secures Product Patent in Australia and Israel

**HYDERABAD, INDIA (June 22, 2020)** – Suven Life Sciences Ltd (Suven) secures one (1) product patent from Australia (2017319609) and one product patent from Israel (250412) corresponding to the new Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2037 and 2034 respectively.

The granted claims of the patents include the class of selective M1PAM compounds H3 inverse agonists respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia etc.

***Disclaimer and Risk Statement:***

***Any information on Suven Intellectual Properties, Grant of Patents, Publications related to IP/Patents provided herewith is based on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.***

### Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7 Banjara Hills | Hyderabad  
– 500 034 | Telangana | India | CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40  
2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)